European Leukemia Trial Registry
Trial: MIDOKIT

More Details
Scientific Title A single-arm phase II trial to assess the efficacy of Midostaurin (PKC412) added to standard primary therapy in patients with newly diagnosed c-KIT or FLT3-ITD mutated t(8;21) AML - MIDOKIT
Short Title MIDOKIT
Trialgroup SAL
Type of Trial multicentric, single-group, open-label
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age <= 65 years
Status Active
Start of Recruitment 01.05.2012
Leader Ehninger, Prof. Dr. med., Gerhard
Shortprotocol Shortprotocol
Diagnostics

Molecular Genetics
Hämatologisches Labor, Universitätsklinikum Dresden

created 23.10.2012 Janina Rosemeier
changed 30.07.2018 Martina Wolkenfeld
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org